Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.

Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.

http://www.wikidata.org/entity/Q45259348

about

Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential Effect of α -Lipoic Acid on Oxidative Stress in End-Stage Renal Disease Patients Receiving Intravenous Iron.Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms.Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury.Diabetes and alpha lipoic Acid.Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters.Rheology as a Tool to Predict the Release of Alpha-Lipoic Acid from Emulsions Used for the Prevention of Skin Aging Antigenotoxic effect of lipoic acid against mitomycin-C in human lymphocyte cultures.Bioavailability of an R-α-Lipoic Acid/γ-Cyclodextrin Complex in Healthy Volunteers.Effects of epigallocatechin gallate, L-ascorbic acid, alpha-tocopherol, and dihydrolipoic acid on the formation of deoxyguanosine adducts derived from lipid peroxidation.Efficacy of α-lipoic acid in diabetic neuropathy.Emerging role of alpha-lipoic acid in the prevention and treatment of bone loss.α-Lipoic acid as a triglyceride-lowering nutraceutical.Determination of lipoic acid in biological samples.Immunomodulatory activities of alpha lipoic acid with a special focus on its efficacy in preventing miscarriage.α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria.Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation.Pharmacokinetics of different formulations of tioctic (alpha-lipoic) acid in healthy volunteers.

P2860

Q24658099-959A9573-78E0-433F-BF71-5D5527E691DD Q33710883-1BF6F227-FDE9-4C8C-BE30-E3B42B910266 Q34646991-9AD8A86F-1845-4258-AB60-EAD443FAD9D9 Q34730353-94978E3E-5E8A-401A-B8EA-EE16364F48DA Q35564911-0081FD2F-480A-4C03-8E2F-9B98131C2E1B Q36373827-D72F2464-78AF-4C11-9457-E84073BB5B6C Q36415826-7B3C892D-4935-4134-8D14-A751264A19B7 Q37039284-ABF23104-3F73-42B6-A2EA-01019BE80A2A Q37050812-97C97A5A-8D99-4978-A79D-67263D0B1FA1 Q37151284-FA414AB6-E2B4-4094-86B9-7D056652CFDC Q38266297-53525784-5871-45A8-A85D-AFAE1A994C07 Q38507547-FC6267EB-FAA0-4DA1-9FEA-6ADD3F03ADFB Q38559352-23F8CCCF-FDB3-49E1-92DE-927157BC8220 Q38566053-952F2E69-21DF-4C28-A09B-5BC527859158 Q38854377-FAA013EF-D562-4ACD-9FA1-35F63C66AB65 Q42633127-5AC96D7B-D6B4-48A2-9A20-6D31A3E9C2E9 Q45993881-E514B7DF-64E9-4AFD-AA3E-0889EEAEEBDF Q46236692-F2B56C21-7530-4664-9BB5-32EAEA074A67

P2860

Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.

http://www.wikidata.org/entity/Q45259348

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Pharmacokinetics of alpha-lipo ...... e and end-stage renal disease.

@en

Pharmacokinetics of alpha-lipo ...... e and end-stage renal disease.

@nl

type

label

Pharmacokinetics of alpha-lipo ...... e and end-stage renal disease.

@en

Pharmacokinetics of alpha-lipo ...... e and end-stage renal disease.

@nl

prefLabel

Pharmacokinetics of alpha-lipo ...... e and end-stage renal disease.

@en

Pharmacokinetics of alpha-lipo ...... e and end-stage renal disease.

@nl

P1433

Q45259348-7F0AE787-E644-46A4-B747-490792F77470

P1476

Q45259348-81A3E344-5C33-4AD6-9718-A614BCD61B5C

P2093

Q45259348-38DE57B6-6B8E-4D76-8E70-27261363480A

Q45259348-508A1B0A-07F0-48C4-81C1-C0BE441489C7

Q45259348-8F203346-3856-4577-983B-C552843D3A2C

Q45259348-96A81C95-C972-48BB-8644-C7EE98721435

Q45259348-AE57B892-CAFF-46D0-9564-14F8CFE9CDBF

Q45259348-B2A00344-0664-49B7-B4C3-447E4371031F

Q45259348-D7837805-A59C-4734-A39C-715726491622

P2860

Q45259348-17A32425-B9E8-4A4C-B947-0E68CF8492CD

Q45259348-17CD3212-391B-42B1-BE3D-E6F5A741B4ED

Q45259348-1B996D17-EF24-4D03-ABD8-79ACFA970C28

Q45259348-1C11B960-3E16-41C8-8F64-A5428A3B26A6

Q45259348-36278339-B36C-4D7B-9C63-CE04E1DCF051

Q45259348-3AF08C8C-609E-4C35-A88E-1FCD069C9FC9

Q45259348-546B22EE-F1C3-48CC-8F1A-C20810329A6A

Q45259348-5A702331-D1AA-45DA-8D10-CB4BE39325AF

Q45259348-65A21870-3449-4D85-885F-3681AF15D436

Q45259348-686F4AAC-4483-4214-948F-162619F828B8

P304

Q45259348-83AF264F-0684-4CB5-9227-C1A917BFF4CC

P31

Q45259348-BB789E6B-5639-4895-9407-C2CE456F32C5

P356

Q45259348-8BD06383-DC76-4688-8E86-A831F79F8C0A

P433

Q45259348-3BB115C2-EDD1-4866-908F-D4FCE11C22DB

P478

Q45259348-D8D7226B-2204-40E7-8625-8669E6882439

P577

Q45259348-AC4F4B39-F4DE-430E-BCA5-B9FC11791260

P5875

Q45259348-6142ACC4-23F8-4C55-8910-4F8C2F9A9AF4

P698

Q45259348-1460F443-0AB5-4F6A-B572-232ED56D8142

P356

0091270004270792

P1433

The Journal of Clinical Pharmacology

P1476

Pharmacokinetics of alpha-lipo ...... e and end-stage renal disease.

@en

P2093

Christa Preiss

http://www.w3.org/2001/XMLSchema#string

Harald Achenbach

http://www.w3.org/2001/XMLSchema#string

Jens Teichert

http://www.w3.org/2001/XMLSchema#string

Peter Ruus

http://www.w3.org/2001/XMLSchema#string

Rainer Preiss

http://www.w3.org/2001/XMLSchema#string

Robert Hermann

http://www.w3.org/2001/XMLSchema#string

Tina Tuemmers

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

alpha-Lipoic acid as a biological antioxidant.

The effect of chronic renal failure on hepatic drug metabolism and drug disposition.

Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy.

Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.

Lipid metabolism in peroxisomes: enzymology, functions and dysfunctions of the fatty acid alpha- and beta-oxidation systems in humans.

Neuroprotection by the metabolic antioxidant alpha-lipoic acid.

Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice.

Idiopathic dysgeusia; an open trial of alpha lipoic acid (ALA) therapy.

Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers.

P304

313-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270004270792

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8030267

http://www.w3.org/2001/XMLSchema#string

P698

15703366

http://www.w3.org/2001/XMLSchema#string